Limitations of Commercial Blue-Light-Filtering Spectacle Lenses: A Critical Analysis of Spectral Targeting, Melanopsin Relevance, and the Case for Wavelength-Selective Photobiological Eyewear in the Indian Market

Commercial blue-light-filtering (BLF) lenses target 400-450 nm HEV light, but the biologically critical melanopsin absorption peak responsible for circadian regulation and migraine photophobia centres at 480 nm. This critical analysis examines the 30-80 nm spectral mismatch underlying the Cochrane 2023 systematic review's negative conclusions (17 RCTs, 619 participants, Singh et al.). We review the melanopsin action spectrum (Brainard 2001), ipRGC discovery (Berson 2002), dual-pathway migraine mechanism (Noseda 2010, 2016), and melatonin suppression data (Gooley 2011) to establish why 400-450 nm BLF lenses produce clinically insignificant outcomes. We present spectral comparison of Indian market BLF products (Lenskart, Titan Eye Plus, John Jacobs) versus wavelength-selective alternatives: FL-41 backed by NeuroCalm FLX+ technology (Patent IN 202521094370) for migraine, amber filtration (Circadian560, Patent Pending IN 202521120977) for sleep, and HEV-selective filtration (DayActive) for daytime comfort. The paper argues that the distinction between "blue light blocking" and "photobiological filtration" is clinically significant. 5 pages, 2 data tables, 23 peer-reviewed references.

Authors: Dubey S, Choudhary M
Affiliation: Sleepaxa Private Limited, Mumbai, India
DPIIT Recognised | CTRI Registered | Wikidata: Q138837663 | ORCID: 0009-0003-7510-9254